MinorVitamin D analogue (25-hydroxy metabolite)×Alpha and beta blocker (non-selective β + α1)
Updated · Methodology
Mechanism
In the liver, carvedilol is metabolised mainly by CYP2D6 and CYP2C9, and to a lesser extent by CYP3A4 and other enzymes. Its metabolites are excreted mainly in bile. Carvedilol is both a substrate and an inhibitor of P-glycoprotein (P-gp) (Coropres SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Coreg label, US Food and Drug Administration, FDA). In the kidney and other tissues, the enzyme CYP27B1 converts calcifediol (25-hydroxyvitamin D3) into active calcitriol, and CYP24A1 breaks both down into inactive metabolites (Hidroferol SmPC, AEMPS). Cytochrome P450 inhibitors such as ketoconazole, itraconazole and clarithromycin may change calcifediol levels (Rayaldee label, FDA), but the carvedilol documents describe carvedilol as a substrate of these enzymes, not an inhibitor. The carvedilol interaction lists do not include vitamin D or its analogues. Among cardiovascular drugs, the calcifediol SmPC names only thiazide diuretics, verapamil and cardiac glycosides (AEMPS documents for both).
Symptoms
The documents describe no symptoms linked to this combination. Carvedilol can slow the heart rate, slow cardiac conduction and lower blood pressure, including on standing. In people with heart failure, heart failure symptoms and fluid retention may worsen while the dose is being increased (Coropres SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Coreg label, US Food and Drug Administration, FDA). Excess calcifediol causes hypercalcaemia with weakness, drowsiness, loss of appetite, nausea, vomiting, constipation, thirst and passing a lot of urine. Acute hypercalcaemia increases the risk of cardiac arrhythmias and can potentiate the effect of cardiac glycosides on the heart (Hidroferol SmPC, AEMPS; Rayaldee label, FDA).
Management
According to the documents, the combination is acceptable, and the doses of carvedilol and calcifediol need no change. No document names the pair, and neither drug belongs to the groups the other drug's documents warn about (Coropres and Hidroferol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; Coreg and Rayaldee labels, US Food and Drug Administration, FDA). In heart failure, which carvedilol also treats, monitor blood calcium at all times during calcifediol treatment, especially in people taking cardiac glycosides. At the start of treatment, these tests are recommended twice a week (Hidroferol SmPC, AEMPS). If digoxin is also used, check digoxin levels when carvedilol is started, its dose is changed or it is stopped (Coropres SmPC, AEMPS). When calcifediol is started or its dose is changed, monitor calcium and signs of cardiac glycoside toxicity more often (Rayaldee label, FDA). In renal impairment, use calcifediol with caution and check calcium and phosphate regularly (Hidroferol SmPC, AEMPS). In heart failure with low blood pressure, ischaemic heart disease or renal impairment, monitor renal function while the carvedilol dose is being increased (Coropres SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Coreg section 7 (2017)– ; DailyMed setid 07c619c6-4a0c-445e-94fa-664a54f68a39
- AEMPS: Ficha técnica: Carvedilol, Coropres 25 mg comprimidos (nº registro 59695), sección 4.5 (2025)– AEMPS, CIMA, nº registro 59695 (Coropres 25 mg comprimidos, Cheplapharm), revisión 07/2025, secciones 4.1, 4.2, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Calcifediol, Hidroferol 0,266 mg cápsulas blandas (nº registro 80095), sección 4.5 (2025)– AEMPS, CIMA, nº registro 80095 (Hidroferol 0,266 mg cápsulas blandas, Faes Farma), revisión 06/2025, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: Rayaldee (calcifediol) prescribing information (2024)– FDA, DailyMed setid 6a95effd-32a5-46b6-a30e-7f4f9bf8cc77 (OPKO Pharmaceuticals), revised 01/2024 (version 11), sections 4, 5.1, 5.2, 7 and 12.3